An Open‐Label, Randomized Comparison of Elvitegravir‐Cobicistat‐Tenofovir Alafenamide-Emtricitabine Versus Efavirenz‐Tenofovir Disoproxil Fumarate‐Lamivudine in Patients Starting Antiretroviral Therapy on the Day of HIV Diagnosis

Trial Profile

An Open‐Label, Randomized Comparison of Elvitegravir‐Cobicistat‐Tenofovir Alafenamide-Emtricitabine Versus Efavirenz‐Tenofovir Disoproxil Fumarate‐Lamivudine in Patients Starting Antiretroviral Therapy on the Day of HIV Diagnosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2018

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top